Vancouver, BC - TheNewswire - May 9, 2023 - AREV Life Sciences Global Corp. (CSE:AREV) (OTC:AREVF) (“AREV” or the Company”) AREV Life Sciences is pleased to announce it has completed its first phase of AI driven deductive research to identify the best complimentary natural compounds for use with its proprietary extracts and Combination Therapy in traditional medicine.

Arev has written and refined an exclusive library of Artificial Intelligence “AI” prompts for the rapid retrieval of data on the most researched and published medicinal compounds. These prompts were ran through fine tuning iterations and backtested using Open AI’s GPT 4.0 language platform. The Arev library has been optimized to: 1) Identify the most researched natural occurring compounds that have synergistic chemistry with Arev’s proprietary extracts, 2) summarize the published research as it relates to the area of targeted health, 3) denote the original source where the compound is found in nature 4) denote any known pharmacokinetics and pharmacodynamics and 5) list references and citations from the published work the results came from, 6) compile a list of the best compounds to use in combination therapy with traditional medicine.

In the first phase of AI analysis, the proprietary prompts instructed the AI agents to act as experts and conduct a deep review of the top researched (peer reviewed and published) compounds used in pre-clinical and clinical trials and studies on multiple categories of diseases. The category of compounds included  botanical extracts, cannabis sativa L and its individual cannabinoids, lipids, including Omega 3,6,7,9,  krill oil and MCT oil, phosphocholine and phosphatidylcholine, polysaccharides, cerebrosides, vitamins and minerals, amino acids, fungi, flavonoids, carotenoids, phytosterols, terpenes and polyphenols.  As a result, we now  have a list of the top ten researched compounds from each of the chemical categories for using with our proprietary extracts in conjunction with Combination Therapy with traditional medicine used to treat the diseases noted below.

Arev’s proprietary extracts contain a rich source of bioactive molecules that possess diverse pharmacological properties for use as a therapeutic effect for (but not limited to) the following areas of health; anti-inflammatory, analgesic, heart disease, cancer(s), hepatoprotective agents for Non Alcoholic Fatty Liver Disease, Fibromyalgia, viral infections and immune deficiencies, anxiety, insomnia, pain-related Inflammation, Alzheimer's (cognitive decline) and wound-healing. Sea cucumber, hops, hemp and ginseng extracts for example, have been researched and validated to possess various biological activities that make them suitable for use in combination therapies with other compounds and improve the efficacy of traditional medicine.

As noted in the British Pharmacological Society Journals - Concise Guide to Pharmacology, “Combination therapies exploit the chances for better efficacy, decreased toxicity, and reduced development of drug resistance and owing to these advantages, have become a standard for the treatment of several diseases and continue to represent a promising approach in indications of unmet medical need. In this context, studying the effects of a combination of drugs in order to provide evidence of a significant superiority compared to the single agents is of particular interest.” Source: https://bpspubs.onlinelibrary.wiley.com/doi/10.1002/prp2.149 

Through phase one we observed theoretical evidence that Arev extracts can benefit from combination therapies as noted in the Analysis of Drug Combinations paper published in the Concise Guide to Pharmacology. The results of this first phase, generated a body of work that serves as a resource to be referred to when looking to match a researched compound with an Arev extract to a specific symptom of a disease. The pharmacokinetics have been cross examined as well to minimize potential drug interactions that may occur when using these compounds with traditional medicine. This is a critical piece that supports the methods and technology Arev has developed. Arev continues to build on its core competencies of extraction and formulation with advanced technology as it prepares for the commercialization of its science backed compounds and ingredients.

The company now has a valuable library of prompts that can be used as is or modified to instruct AI agents to identify compounds and their pharmacokinetics to determine their efficacy and synergistic relations to other compounds for application in targeted areas of health when used with Arev extracts for optimal results in combination therapy. These prompts can be applied to further AI deductive work with extracts combined with other compounds or even to identify potential drug candidates. Having these tools enable Arev to perform work that would normally take a team of researchers months and in some cases years to complete.

CEO, Michael Withrow stated “Without the deployment of AI, this type of work, would be too time consuming and just not feasible for companies like Arev to do what multi billion dollar food and drug companies do manually in this area as a normal course of business.” He went on to say, “The use of AI technology on the chemistry of compounds provides Arev (and other who adopt it) with the ability to identify combination therapies for use as natural therapeutic interventions in clinical nutrition, natural health products, functional foods and beverages. These industries and their consumers both stand to benefit greatly with the implementation of AI.”

The nutritional profile of functional foods and beverages can be improved and carry structured function claims with the application of this game changing technology. New products can be manufactured (processed), packaged and sold to consumers.

The company claims copyright ownership of its exclusive library of Artificial Intelligence Instructions “Prompts” and plans to register the library and method internationally. The board plans to seek council from its Intellectual Property Attorney’s to draft licensing agreements for the use of this method and library of IP.  

For further information, contact Mike Withrow, This email address is being protected from spambots. You need JavaScript enabled to view it. 778-929-6536. For more information visit www.arevlifesciences.com.  

On behalf of the Board, 

Mike Withrow
CEO & Director

About AREV Life Sciences Global Corp.

The Company is a fully integrated enterprise with competencies in: 1) extraction of compounds for consumption and topical use. 2) Clinical Nutrition and 3) A technology platform called Medicine Merchant. The Company produces ingredients and formulates exclusive therapeutic interventions with plans to deliver innovation in clinical nutrition, proprietary supplements, topicals and rational drug design, based on science. The Company’s business model leverages its core competency of extraction to produce ingredients and compounds for its pipeline of products. The Company continues in the product development and pre-commercialization stage. 

AREV is dedicated to designing and delivering innovation in rational drug design, driven by presenting global epidemiological characteristics of multiple challenges to international human and animal health. AREV is a member of both BIOTECanada and The Biotechnology Innovation Organization (BIO).  

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.  

FORWARD LOOKING INFORMATION

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, and continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required

under the applicable laws. This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements.  Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements

address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com.